Summary
Biogen Inc. (BIIB) filed an 8-K on April 25, 2023, primarily to report its first-quarter 2023 financial results and operational updates. The company issued a press release on the same day, which is furnished as part of this filing. Investors should refer to this press release for detailed financial performance metrics, including revenue, earnings, and any forward-looking guidance provided by the company for the upcoming periods. This filing serves as the official channel for disseminating these critical quarterly updates.
Key Highlights
- 1Biogen announced its first-quarter 2023 financial results on April 25, 2023.
- 2The 8-K filing incorporates a press release containing the detailed Q1 2023 results.
- 3This filing is primarily an informational disclosure of financial performance.
- 4Investors should review the furnished press release for specific financial figures and operational commentary.
- 5The information provided is furnished and not deemed 'filed' for regulatory liability purposes under Section 18 of the Exchange Act.
- 6Exhibit 99.1 contains the press release announcing Q1 2023 results.
Frequently Asked Questions
The main purpose of this 8-K filing is to formally report Biogen Inc.'s financial results and operational condition for the first quarter ended March 31, 2023, through the incorporation of a press release.
The detailed financial results and operational updates for the first quarter of 2023 are available in the press release furnished as Exhibit 99.1 to this 8-K filing.
No, the press release furnished pursuant to Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that Section. It is furnished for informational purposes.
This means that the press release (Exhibit 99.1) is included with the 8-K filing, and its content is considered part of the filing for investors to review, but it retains its 'furnished' status rather than being formally 'filed' with the SEC.